
Roche’s haemophilia A drug shows meaningful bleed control in P3
pharmafile | December 7, 2017 | News story | Research and Development | Roche, haemophilia, pharma
Roche has unveiled new Phase 3 data for its haemophilia A treatment Helimbra (emicizumab) in patients over 12 years of age with the condition without inhibitors to factor VIII, showing that the prophylaxis therapy produced clinically meaningful control of bleeding when used once every four weeks.
Helimbra, a bispecific factor IXa- and factor X-directed antibody, was tested in 48 haemophilia A patients with or without inhibitors to factor VIII or bypassing agents, on-demands or as prophylaxis. The new data proved consistent with earlier studies of the drug in doses of once weekly or every two weeks.
Full data from the study is due to be presented at an upcoming medical meeting, with authorisation applications in global markets to follow.
“Current treatment regimens for haemophilia A can require frequent intravenous infusions. We are encouraged that Hemlibra prophylaxis administered by injection under the skin once every four weeks showed clinically meaningful bleed control in people with haemophilia A,” commented Sandra Horning, Chief Medical Officer and Head of Global Product Development at Roche. “Together with the findings from other phase III studies, these interim results support the potential for Hemlibra to be dosed at different schedules, allowing patients to choose the option that’s right for them.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …






